利福昔明治疗急性细菌性肠道感染107例

Treatment of 107 Cases of Acute Bacterial Infection of the Intestine with Rifaximin

目的 评价利福昔明治疗急性细菌性肠道感染疾病的疗效和安全性。方法 采用多中心随机双盲双模拟平行对照试验。急性细菌性肠道感染患者 211例,随机分为两组,治疗组 107例,每次给予利福昔明 0. 2g,po,q6h,同时给予环丙沙星模拟安慰药片 1片,bid,疗程 5d;对照组 104例每次给予环丙沙星 0 .25g,po,bid,同时给予利福昔明模拟安慰药片 2片,po,q6h,疗程 5d。评价两药的疗效及不良反应。结果 治疗组肠道感染的治愈率和显效率分别是 75 7%和 18 .7%,总有效率为 94 .4%;对照组分别是 84 .6%和 13 .5%,总有效率为 98 .1%。利福昔明和环丙沙星的细菌清除率分别是 96. 2%和 96 3%,不良反应发生率为 2. 8%和 2. 9%。各项结果的差异均无显著性 (P>0 .05)。结论 利福昔明治疗急性细菌性肠道感染具有较好的疗效,不良反应发生率低,与环丙沙星的疗效相仿。

Objective To assess the therapeutic efficiency and safety rate of rifaximin in the treatment of acute bacterial infection of the intestine. Methods A multicentre, random, double blind and double dummy parallel control protocol was employed in the trial. 211 patients with acute bacterial infection of the intestine were randomly divided into the treatment group and control group. 107 cases in the treatment group were given each 0.2 g of rifaximin, PO, q.6 h. and 1 ciprofloxacin dummy tablet, PO,b.i.d.. 104 cases in the control group were given each 0.25 g of ciprofloxacin, PO, b.i.d. and 2 rifaximin dummy tablets,q.6 h.. The course of treatment in both groups lasted 5 days.The therapeutic efficiency of the 2 drugs was appraised. Results The overall effective rates in patients of the treatment group and control group were 94.4% and 96.1%,respectively, while the corresponding cure rates were 75.7% and 84.6%,respectively. The bacteria elimination rates were 96.2% and 96.3%,respectively, and the incidences of adverse reactions were 2.8% and 2.9%, respectively. Differences between the two groups were not statistically significant( P >0.05). Conclusion Rifaximin was shown to be effective and safe in the treatment of acute bacterial infection of the intestine. Its adverse reactions were rare and mild. The therapeutic efficiency and safety rate of rifaximin were similar to those of ciprofloxacin.